Unclear How FDA Commissioner Makary’s Departure Will Impact Policy
Food and Drug Administration commissioner, Dr. Marty Makary, made headlines this week with his announcement of resignation after a tumultuous 13-month tenure at the agency. During his time in office, Makary pursued a wide array of ambitious initiatives and regulatory changes, some of which were met with controversy. As the next commissioner steps in, the fate of these initiatives remains uncertain.
One of the key areas Makary focused on was increasing transparency within the FDA and reducing regulatory barriers to accelerate drug development pathways. He also collaborated with the Make America Healthy Again movement to address chronic disease prevention. Additionally, Makary initiated programs to reduce animal testing, phase out certain chemical dyes in food, streamline biosimilar development, and ease regulations for therapies targeting ultra-rare diseases.
One of the most significant changes Makary implemented was the shortening of clinical trial timelines by allowing single-study drug approvals. Traditionally, drugmakers had to complete two large-scale studies to demonstrate a new medication’s effectiveness and safety. Makary’s policy shift towards accepting one robust clinical trial, especially in areas like oncology, rare diseases, and cell and gene therapy, marked a significant departure from previous FDA practices.
Makary also advocated for the codification of the rare pediatric disease priority review voucher program, which expedites the regulatory review process for new pharmaceuticals. However, his support for expedited reviews for drugs aligned with “U.S. national priorities” drew criticism for potentially allowing political influence in the FDA’s decision-making process.
In terms of transparency, Makary took proactive steps such as publicly posting Complete Response Letters and cracking down on deceptive drug advertising. He also pushed for full safety disclosures in direct-to-consumer drug commercials, a move aimed at ensuring that consumers have access to accurate and comprehensive information.
Despite his reform efforts, Makary’s tenure was marked by chaos, including a high turnover of top agency officials and controversial policy decisions. His support for unproven therapies and unconventional approaches to issues like vaccines and dietary guidelines raised concerns within the scientific community.
As Makary steps down, Kyle Diamantas, the former deputy commissioner for food at the FDA, will serve as acting commissioner. Diamantas, a former lawyer without medical training, faces the challenge of navigating the ongoing turmoil within the FDA and broader health department. The selection of the next permanent commissioner will be crucial in determining the future direction of the agency and addressing concerns of political interference in decision-making processes.
